Gilead Sciences, Inc. $GILD Shares Acquired by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 595,236 shares of the biopharmaceutical company’s stock after acquiring an additional 111,218 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Gilead Sciences were worth $69,512,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. GoalVest Advisory LLC lifted its position in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences during the second quarter worth about $27,000. Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. Finally, Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 136,757 shares of company stock worth $16,951,612 in the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $1.65 on Tuesday, reaching $123.26. 662,669 shares of the company were exchanged, compared to its average volume of 6,034,411. The company has a 50-day moving average of $123.49 and a 200-day moving average of $118.20. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm has a market cap of $152.92 billion, a price-to-earnings ratio of 19.09, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. Gilead Sciences, Inc. has a 1-year low of $91.84 and a 1-year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the firm earned $2.02 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GILD shares. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. TD Cowen upped their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. UBS Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday. Truist Financial assumed coverage on shares of Gilead Sciences in a report on Monday, November 24th. They issued a “buy” rating and a $140.00 price objective on the stock. Finally, Scotiabank started coverage on Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $133.28.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.